Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -31,069 | -20,641 | -11,527 | -38,776 | -28,142 |
| Depreciation Amortization | 24 | 16 | 32 | 32 | 24 |
| Other Working Capital | -256 | -1,771 | -873 | 4,968 | 2,119 |
| Other Operating Activity | 3,038 | 1,770 | 1,575 | 2,720 | 2,182 |
| Operating Cash Flow | $-28,263 | $-20,626 | $-10,793 | $-31,056 | $-23,817 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 20,000 | 20,000 | 10,000 | 10,000 | 0 |
| Common Stock Issued | 10,033 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $30,033 | $20,000 | $10,000 | $10,000 | $0 |
| Beginning Cash Position | 18,592 | 18,592 | 18,592 | 39,648 | 39,648 |
| End Cash Position | 20,362 | 17,966 | 17,799 | 18,592 | 15,831 |
| Net Cash Flow | $1,770 | $-626 | $-793 | $-21,056 | $-23,817 |
| Free Cash Flow | |||||
| Operating Cash Flow | -28,263 | -20,626 | -10,793 | -31,056 | -23,817 |
| Free Cash Flow | -28,263 | -20,626 | -10,793 | -31,056 | -23,817 |